SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-018713
Filing Date
2021-04-13
Accepted
2021-04-13 16:24:34
Documents
62
Period of Report
2021-02-28

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-10q_20210228.htm 10-Q 2337905
2 EX-31.1 nrix-ex311_28.htm EX-31.1 19981
3 EX-31.2 nrix-ex312_27.htm EX-31.2 19971
4 EX-32.1 nrix-ex321_26.htm EX-32.1 15647
  Complete submission text file 0001564590-21-018713.txt   6859539

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nrix-20210228.xml EX-101.INS 1312385
6 XBRL TAXONOMY EXTENSION SCHEMA nrix-20210228.xsd EX-101.SCH 46628
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nrix-20210228_cal.xml EX-101.CAL 41928
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrix-20210228_def.xml EX-101.DEF 137583
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20210228_lab.xml EX-101.LAB 371639
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20210228_pre.xml EX-101.PRE 273136
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 21823331
SIC: 2834 Pharmaceutical Preparations